Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 5/20 | 0.74 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.74 |
| ▸ | ACHE | P22303 | 5/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.43 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29800074 | 1.00 | EDNRA (0.74) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL26688800 | 0.95 | EDNRA (0.66) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL30757414 | 0.95 | EDNRA (0.66) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL5525535 | 0.94 | AGTR1 (0.65) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL30844558 | 0.94 | EDNRA (0.65) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL5530293 | 0.94 | AGTR1 (0.66) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL25084458 | 0.94 | AGTR1 (0.65) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL30844520 | 0.94 | AGTR1 (0.65) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL30844543 | 0.93 | AGTR1 (0.64) | EDNRAAGTR1ACHEAGTR2LTB4R2 | |
| SCHEMBL27420170 | 0.93 | AGTR1 (0.64) | EDNRAAGTR1ACHEAGTR2LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210196688-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Travere Therapeutics, Inc. | 2021-07-01 | — | — | US | disclosed |
| US-10864197-B2 | Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders | Retrophin, Inc. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3708163-A1 | USE OF SPARSENTAN FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Ligand Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200281901-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Travere Therapeutics, Inc. | 2020-09-10 | — | — | US | disclosed |
| EP-3222277-B1 | A BIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONIST TO TREAT GLOMERULOSCLEROSIS AND IGA-INDUCED NEPHROPATHY | LIGAND PHARM INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190262317-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Retrophin, Inc. | 2019-08-29 | — | — | US | disclosed |
| US-20180344705-A1 | METHOD FOR TREATING CHRONIC INFLAMMATORY DISEASES | LIGAND PHARMACEUTICALS INC. | 2018-12-06 | — | — | US | disclosed |
| US-9993461-B2 | Method for treating disorders associated with glomerular function | LIGAND PHARMACEUTICALS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| WO-2018071784-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Retrophin, Inc. (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20170354646-A1 | METHOD FOR TREATING DISORDERS ASSOCIATED WITH GLOMERULAR FUNCTION | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-12-14 | — | — | US | disclosed |
| WO-2010114801-A1 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY | LIGAND PHARMACEUTICALS INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114801-A1 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY | LIGAND PHARMACEUTICALS INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| EP-1741713-A2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | Bristol-Myers Squibb Company (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1237888-B1 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2006-09-13 | — | — | EP | disclosed |
| US-6852745-B2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-08 | — | — | US | disclosed |
| US-6835741-B2 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-28 | — | — | US | disclosed |
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-06-03 | — | — | US | disclosed |
| US-6638937-B2 | As antihypertensive agents; for therapy of disorders related to renal, glomerular and mesangial cell function; therapy of endotoxemia or endotoxin shock as well as hemorrhagic shock; useful in alleviation of pain associated cancer | BRISTOL-MYERS SQUIBB CO. | 2003-10-28 | — | — | US | disclosed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | EDNRA 3/4885AGTR1 4/4885ACHE 1584/4885 |
| US-20180344705-A1 | METHOD FOR TREATING CHRONIC INFLAMMATORY DISEASES | AGTR2, AGTR1, EDNRA | EDNRA 3/4885AGTR1 2/4885ACHE 854/4885 |
| US-20200281901-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | REN, ATP6V1B1, VHL | EDNRA 706/4885AGTR1 35/4885ACHE 3861/4885 |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | EDNRA 3/4885AGTR1 4/4885ACHE 1584/4885 |
| US-20190262317-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | REN, SULT2A1, ARSA | EDNRA 230/4885AGTR1 100/4885ACHE 3981/4885 |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | EDNRA 3/4885AGTR1 4/4885ACHE 1584/4885 |
| US-10864197-B2 | Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders | REN, ATP6V1B1, VHL | EDNRA 706/4885AGTR1 35/4885ACHE 3861/4885 |
| US-20210196688-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | REN, ATP6V1B1, VHL | EDNRA 706/4885AGTR1 35/4885ACHE 3861/4885 |
| US-20170354646-A1 | METHOD FOR TREATING DISORDERS ASSOCIATED WITH GLOMERULAR FUNCTION | REN, AGTR2, AGTR1 | EDNRA 6/4885AGTR1 3/4885ACHE 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.